Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug

All NewsApril 24, 2026

Grace Therapeutics stock drops after FDA flags NDA issues for GTx-104; CMC concerns weigh despite no request for additional clinical data.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent